Australian Infrastructure Investment and Privatisation Update: Federal Taxation on the Agenda

whitePaper | January 22, 2020

Trade in “services” refers to a wide and growing range of economic activities. These activities include transport, tourism, financial services, use of intellectual property, telecommunications and information services, government services, maintenance, and other professional services from accounting to legal services. Compared to goods, the types and volume of services that can be traded are limited by factors such as the requirement for direct buyer-provider contact, and other unique characteristics such as the reusability of services (e.g., professional consulting) for which traditional value measures do not account. In addition to services as independent exports, manufactured and agricultural products incorporate and depend on services, such as research and development or shipping of intermediate or final goods. As services account for 71% of U.S. employment, U.S. trade in services, both services as exports and as inputs to other exported products, can have a broad impact across the U.S. economy.

whitePaper | December 1, 2022

The business of providing information and communications technology (ICT) integrations to governments has changed significantly over the past five years. Before the disruptions caused by the pandemic, government ICT requirements were well-understood. Most government departments were in the process of either starting or planning for a cloud-centric digital transformation that would enable more efficient operations and a more effective delivery of services to citizens. However, the onset of the pandemic derailed most of those plans when the key priority shifted to finding ways for government employees to continue to do their jobs remotely

whitePaper | March 30, 2022

Why have we written disparaging statements about government when our firm is so deeply committed to public sector excellence? These include statements like “as the fire rages on, our governments seem powerless” and “hunches no longer pass for evidence these days, unless we’re talking about government policy.” We have compared the policy-making process to a chaotic game of tag and suggested that government policymakers can act as seemingly irrational as Cosmo Kramer did on Seinfeld.

whitePaper | February 3, 2020

Protecting sensitive data and maintaining cybersecurity hygiene are top concerns for security professionals and CISOs from state and local government agencies. Government networks contain sensitive data such as social security numbers, voter registration, medical records, bank account and credit card numbers of millions of people and businesses, which can make them an attractive target for bad actors. With the increasing sophistication of cyberattacks and the lack of resources at their disposal, the IT departments across these agencies are looking for a solution that enables them to do more with less. We built Duo to be a simple, affordable and secure solution to help government agencies – and organizations of all sizes – solve to these problems.

whitePaper | March 16, 2022

A long-term commitment to sustained federal research and development (R&D) funding in AI is critical to advance the United States’ leadership in global innovation. The federal government should increase non-defense investment in AI and basic research to strengthen research in critical fields of AI R&D, including healthcare, education, finance, and more, that underpin economic stability and robust growth. Such investment should reflect a multidisciplinary approach, focused on advancing basic and applied R&D, research on AI governance and norm-setting, and supporting research infrastructure with multi-agency collaboration.

whitePaper | February 12, 2020

Both the U.S. Government and biopharmaceutical industry have been central engines for developing new medical treatments and cures, thereby lowering the effective price of better health for patients worldwide. The sector has done so by being both the world leader in these biopharmaceutical cures and treatments as well as the source of the returns that are required to fund new medical R&D investments.